###  [:house:返回首頁](https://github.com/ourhimalayas/txt)
---


## 老药新用：乙酰半胱氨酸（NAC）不仅治疗冠状病毒感染，还有可能解毒疫苗
` 波士顿五月花农场` [轉載自GNews](https://gnews.org/zh-hans/2223845/)

作者：波士顿五月花 北美教练陪练
![](https://assets.gnews.org/wp-content/uploads/2022/03/17C0F8B3-B86F-406A-B176-B3A9EE351198.jpg)
N-乙酰半胱氨酸(N -Acetylcysteine ，NAC)在临床已经应用了30 多年。是祛痰类老药。它的祛痰机理：NAC含巯基，可断裂粘蛋白肽键的二硫键（-S-S-），粘蛋白变成小分子肽链，使得痰液的粘滞性降低，易于咳出，最初主要用于呼吸系统疾病。多年临床研究已经证，NAC不仅仅是一种黏液溶解药，还具有多种生物活性，NAC这一老药已经焕发出出勃勃生机，已经报道的治疗范围几乎囊括所有的人类疾病。尤其对药物及重金属中毒、艾滋病、癌症、心脏病，糖尿病、帕金森病、自身免疫性疾病等各种难治疾病都有疗效。虽然NAC有点像个万能药，但它是个货真价实的、有效的、无害的好药，尤其是对许多药物中毒，例如醋氨酚（解热止痛药）中毒的最有效解毒药物就是NAC（1-31）。

在美国， NAC原本是非处方药。但病毒疫情爆发后，FDA 在2020年7月却连发多封警告信，不许在市场销售。联想到FDA在兜售疫苗中扮演的不光彩角色，逆向思维，那么NAC一定是治疗冠状病毒的有效药物！现将NAC治疗冠状病毒和解毒疫苗的可能性与读者们分享。

**NAC是谷胱甘肽前体，在体内转化成谷胱甘肽。
**
谷胱甘肽（GSH）是由谷氨酸、半胱氨酸和甘氨酸通过肽键缩合而成的三肽化合物，广泛存在于人体内，其在细胞内浓度可达０．５～１０ｍｍｏｌ／Ｌ。在生理条件下，谷胱甘肽主要以还原型谷胱甘肽（ＧＳＨ）和氧化型谷胱甘肽（ＧＳＳＧ）两种形式，其中有活性的ＧＳＨ约占９０％。半胱氨酸中的巯基易被氧化脱氢，是赋予谷胱甘肽广谱解毒作用的活性中心基团，能中和各种有毒化合物、重金属离子或致癌物质等，并促其排出体外。半胱氨酸中的巯基还可保护细胞膜，对维持细胞内氨基酸转运、糖代谢和调节DNA合成、维护免疫细胞功能、保护细胞免受各种损伤等方面发挥着重要作用。

尤其重要的是GSH 的含量与许多病毒复制有关。例如，Herzenberg等发现，GSH含量降低会损伤T淋巴细胞功能，促进艾滋病病毒复制。CD4 T细胞中GSH含量低，艾滋病病人寿命缩短。GSH是衡量艾滋病病人病情进展与否和生存期的指标之一（32）（33）。

然而，口服或注射谷胱甘肽不容易进入细胞内。NAC是谷胱甘肽前体，在体内可以转化成谷胱甘肽。临床证实NAC能被细胞吸收，可以有效补充过度消耗的谷胱甘肽。

**冠状病毒的易感人群细胞谷胱甘肽含量低。
**
疫情肆虐2年多以来，现在已经非常清楚了，冠状病毒的易感人群包括老年人、糖尿病和各种基础疾病患者。易感人群患病后，最容易变为重症甚至死亡。所有这些易感人群的一个共同特点就是细胞内谷胱甘肽水平常常会很低 (34-42)。Polonikov （43）观察到谷胱甘肽含量越少，冠状病毒感染病情越严重，他认为谷胱甘肽含量低是容易感染冠状病毒和病死的主要原因。

冠状病毒侵入细胞内复制会进一步消耗谷胱甘肽，严重的冠状病毒感染甚至会使谷胱甘肽消耗殆尽(44)。Khanfar 和Qaroot 认为谷胱甘肽消耗殆尽后，细胞就会像一个特洛伊木马，冠状病毒复制就会失控，所以谷胱甘肽消耗殆尽是重症病人死亡的原因（45）。

**NAC治疗抗许多病毒感染，包括冠状病毒感染。
**
体外和体内实验都证明NAC具有灭活流感病毒的作用（46）（47）(48)。NAC 还有灭活登革热病毒和单纯疱疹病毒的作用（49）（50）(51)。在艾滋病潜伏期模型研究中，NAC 能抑制巨噬细胞中艾滋病病毒的复制，尤其要特殊强调的是，这一研究出自美国国立卫生研究院福奇带领的研究团队（52）。NAC 还能减弱反转录病毒的传然性（53）（54）。

Bhattacharya（55）研究了164例重症冠状病毒感染患者， 结果表明，静脉滴注NAC，每日三次，每次 1克，可缩短住院时间、减少死亡人数。Gaynitdinova（56）研究了46重症冠状病毒感染患者， 结果表明，静脉滴注NAC，每日1200-1500毫克，可以显著提高血氧饱和度， 减少肺损伤，缩短住院时间；同时可降低炎症反应指标C反应蛋白。Assimakopoulos（57）研究了82例冠状病毒感染患者, 结果表明，口服NAC 每日两次，每次600 mg，连续14天，可有效阻止病情恶化，显著降低死亡率。

**NAC解毒毒疫苗的理论依据。
**
所有疫苗毒性主要由刺突蛋白（S蛋白）引起。Wrapp 发现S蛋白主要部位共含有14个二硫键（58）。受体结合区（RBD）是S蛋白致病的关键部位所在。RBD中共发现九个半胱氨酸残基，其中八个形成四对二硫键。二硫键是比较稳定的共价键，在蛋白质分子中，起着稳定肽链空间结构的作用。二硫键数目越多，蛋白质分子对抗外界因素影响的稳定性就愈大。在这四对中，核心有三对于稳定S蛋白结构起到决定性的作用 （59）。

NAC 的巯基（SH）就像一把刀，可以破环二硫键，解体RBD，使S蛋白功能丧失（60）(61) 。S蛋白功能丧失既意味着疫苗毒性丧失。当然，是否真的能解疫苗毒，还有待最终临床实验证实。

如果mRNA 疫苗如果被整合到人类染色体的话，人体会不断产生S蛋白。这就需要不断的用NAC类药物清除。永久性的清除被整合到人类染色体的S蛋白毒基因有赖于分子生物学的技术的进展，例如基因编辑等，精准的敲除S蛋白毒基因，但这需要时间和科研的大量投入。在毒疫苗即将引发大规模人道灾难的当下， 认识到NAC的潜在价值显得十分有意义。

**在此特别声明：治疗疾病应找医生咨询，读者自行治疗产生的任何事故，笔者概不负责。**
![](https://assets.gnews.org/wp-content/uploads/2022/03/图片1-125.jpg)
图1、NAC化学结构，巯基（SH）好像一把刀砍向S蛋白的二硫键
![](https://assets.gnews.org/wp-content/uploads/2022/03/图片2-48.jpg)
图2、二硫键



**参考文献：**

1. N-Acetylcysteine: A Review of Clinical Usefulness (an Old Drug with New Tricks) Journal of Nutrition and Metabolism Volume 2021, 9949453, 13 pages
2. Mokhtari V et al. A Review on Various Uses of N-Acetyl Cysteine. Cell J. 2017 Apr-Jun; 19(1): 11–17.
3. Henderson P et al. N-Acetylcysteine therapy of acute heavy metal poisoning in mice. Vet Hum Toxicol. 1985 Dec;27(6):522-5.
4. Heard KJ. Acetylcysteine for Acetaminophen Poisoning. N Engl J Med. 2008 Jul 17; 359(3): 285–292.
5. Algren DA et al. REVIEW OF N-ACETYLCYSTEINE FOR THE TREATMENT OF ACETAMINOPHEN (PARACETAMOL) TOXICITY IN PEDIATRICS. Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines Geneva, 29 September to 3 October 2008.
6. Chiu MH et al. Massive Acetaminophen Overdose Treated Successfully with N-Acetylcysteine, Fomepizole, and Hemodialysis. Case reports in critical care https://doi.org/10.1155/2021/6695967
7. Quintanilla ME et al. N-Acetylcysteine and Acetylsalicylic Acid Inhibit Alcohol Consumption by Different Mechanisms: Combined Protection. Front. Behav. Neurosci., 31 July 2020 | https://doi.org/10.3389/fnbeh.2020.00122
8. Tomko RL et al. N-acetylcysteine: A potential treatment for substance use disorders. Curr Psychiatr. 2018 Jun; 17(6): 30–55.
9. Israel Y et al. Aspirin and N-acetylcysteine co-administration markedly inhibit chronic ethanol intake and block relapse binge drinking: Role of neuroinflammation-oxidative stress self-perpetuation. Addict Biol 2021 Jan;26(1):e12853.
10. Zandwijk NV N-acetylcysteine (NAC) and glutathione (GSH): antioxidant and chemopreventive properties, with special reference to lung cancer. J Cell Biochem Suppl 1995;22:24-32
11. Smilkstein MJ et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study. N Engl J Med. 1988; 319: 1557-1562
12. Woo OF et al. Short duration of oral N acetylcyteine therapy for acute acetaminophen overdose. Toxicology 2000 35:363-368
13. Ballatori N et l. N-acetylcysteine as an antidote in methylmercury poisoning. Environ Health Perspect. 1998 May; 106(5): 267–271.
14. Rossignol D.A. (2019) The Use of N-Acetylcysteine as a Chelator for Metal Toxicity. In: Frye R., Berk M. (eds) The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine. Adis, Singapore. https://doi.org/10.1007/978-981-10-5311-5\_10
15. Muldoon LL et al. N-acetylcysteine chemoprotection without decreased cisplatin antitumor efficacy in pediatric tumor models. J Neurooncol 2015 121:433-40
16. Giampreti A et al. N-Acetyl-Cysteine as Effective and Safe Chelating Agent in Metal-on-Metal Hip-Implanted Patients: Two Cases. Case report in orthopedics https://doi.org/10.1155/2016/8682737
17. Mokhtari V et al. A Review on Various Uses of N-Acetyl Cysteine. Cell J. 2017 Apr-Jun; 19(1): 11–17.
18. Tomko RL. N-acetylcysteine: A potential treatment for substance use disorders. Curr Psychiatr. 2018 Jun; 17(6): 30–55.
19. Tattersall AB, Bridgman KM, Huitson A. Acetylcysteine (Fabrol) in chronic bronchitis—a study in general practice. J Int Med Res. 1983;11(5):279–284.
20. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J. 2004;23(4):629–636.
21. Lundbäck B et al. Possible effect of acetylcysteine on lung function. Eur Respir J. 1992;5(suppl 15):289s.
22. Stey C et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J. 2000;16(2):253–262.
23. De Flora S et al. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J. 1997;10(7):1535–1541.
24. Demedts M et al., for the IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353(21):2229–2242.
25. Marenzi G et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354(26):2773–2782.
26. Rizk AY et al. N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome. Fertil Steril. 2005;83(2):367–370.
27. Badawy A et al. N-Acetyl cysteine and clomiphene citrate for induction of ovulation in polycystic ovary syndrome: a crossover trial. Acta Obstet Gynecol Scand. 2007;86(2):218–222.
28. Martina V et al. Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care. 2008;31:940–944.
29. Treweeke AT. N-Acetylcysteine inhibits platelet-monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial. Diabetologia. 2012;55:2920–2928.
30. Shahripour RB et al. N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain Behav 2014 4:108-22
31. Monti DA et al. N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory Study.Front. Neurol | https://doi.org/10.3389/fneur.2020.00088
32. Eck H-P, Gmunder H, Hartmann M, Petzoldt D, Daniel V, Droge W. Biol Chem Hoppe-Seyler. 1989;370:101–108. [PubMed] [Google Scholar]
33. Helbling B, Von Overbeck J, Lauterburg B H. Eur J Clin Invest. 1996;26:38–44. [PubMed] [Google Scholar]
34. Julius M et al. Glutathione and morbidity in a community based sample of elderly. Journal of clinical epidemiology. 1994 47:1021-1026.
35. Nicholas O. et al. Glutathione maintenance mitigates age-related susceptibility to redox cycling agents. Redox Biology, 2016; 10: 45 DOI: 10.1016/j.redox.2016.09.010
36. Lutchmansingh FK et al. Glutathione metabolism in type 2 diabetes and its relationship with microvascular complications and glycemia. PLoS One. 2018; 13(6): e0198626.
37. Herzenberg LA et al. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci U S A. 1997 Mar 4; 94(5): 1967–1972.
38. Perricone C et al. Glutathione: a key player in autoimmunity. Autoimmun Rev 2009 8:697-701
39. Koji Aoyama K, Nakaki T. Impaired glutathione synthesis in neurodegeneration. Int J Mol Sci 2013 Oct 18;14(10):21021-44
40. Morris D et al. Glutathione and infection. Biochim Biophys Acta 2013 May;1830(5):3329-49
41. Venketaraman, V. Glutathione levels and immune responses in tuberculosis patients. Microb. Pathog. 2008, 44, e255–e261.
42. Ly, J. et al. Liposomal Glutathione Supplementation Restores TH1 Cytokine Response to Mycobacterium Tuberculosis Infection in HIV-Infected Individuals. J. Interferon. Cytokine Res. 2015, 35, 875–887
43. Polonikov A. Endogenous Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in COVID-19 Patients. ACS Infect. Dis. 2020, 6, 1558−1562
44. Silvagno F. et al. The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19. Antioxidants (Basel) 2020 Jul 16;9(7):624
45. Khanfar A, Qaroot B al. Could glutathione depletion be the Trojan horse of COVID-19 mortality? European Review for Medical and Pharmacological Sciences 2020; 24: 12500-12509
46. Cai J. et al. Inhibition of influenza infection by glutathione. Free Radic Biol Med. 2003; 34: 928-936. 108)
47. Amatore D. et al. Glutathione increase by the n‐butanoyl glutathione derivative (GSH‐ C4) inhibits viral replication and induces a predominant Th1 immune profile in old mice infected with influenza virus. FASEB Bioadv 2019; 1: 296-305.
48. Geiler J. et al. N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol 2010; 79: 413-420.
49. Wang J. et al. Inhibitory effect of glutathione on oxidative liver injury induced by dengue virus serotype 2 infections in mice. PLoS One 2013; 8: e55407. 113)
50. Aubry M. et al. Pathogen inactivation of Dengue virus in red blood cells using amustaline and glutathione. Transfusion 2017; 57: 2888-2896. 114)
51. Palamara AT. et al. Evidence for antiviral activity of glutathione: in vitro inhibition of herpes simplex virus type 1 replication. Antiviral Res 1995; 27: 237-253. 115)
52. Kalebic T. Fauci AS. Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine. Proc Natl Acad Sci U S A 1991; 88: 986-990. 116)
53. Guerrero CA. Inhibition of rotavirus ECwt infection in ICR suckling mice by N-acetylcysteine, peroxisome proliferator-activated receptor gamma agonists and cyclooxygenase-2 inhibitors. Mem Inst Oswaldo Cruz 2013; 108: 741-754. 117
54. Guerrero CA. N‐acetylcysteine treatment of rotavirus‐associated diarrhea in children. Pharmacotherapy 2014; 34: 333-340.
55. Bhattacharya R et al. The beneficial role of N-acetylcysteine as an adjunctive drug in treatment of COVID-19 patients in a tertiary care hospital in India: an observational study. Int J Res Med Sci 2021; 8: 3518-3522.
56. Gaynitdinova VV et al. N-acetylcysteine as a part of complex treatment of moderate COVID-associated pneumonia. Pulmonologiya 2021; 31: 21-29
57. Assimakopoulos SF et al. N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study. Infect Dis (Lond) 2021; 53: 847-854
58. Wrapp, D et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020 367 6483
59. Lan J et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020 581, pages215–220
60. Grishin A et al. Spike protein disulfide disruption as a potential treatment for SARS-CoV-2. https://doi.org/10.1101/2021.01.02.425099
61. Keber MM et al. Disruption of disulfides within RBD of SARS‐CoV‐2 spike protein prevents fusion and represents a target for viral entry inhibition by registered drugs. FASEB J. 2021 Jun; 35(6): e21651.


* * *

*编辑：文合
封面：水涨船高
发布：吐纳*

 

免责声明：本文内容仅代表作者个人观点，平台不承担任何法律风险。

- [ROL Foundation](https://rolfoundation.org/)
- [ROL Society](https://rolsociety.org/)
- [Terms of use](https://gnews.org/terms-of-use-3/)
- [Privacy Policy](https://gnews.org/privacy-policy/)
